Eli Lilly's Donanemab Seeks FDA Approval for Alzheimer's Treatment After Successful Clinical Trials

A new Alzheimer's drug, Donanemab, is set to seek approval from the US Food and Drug Administration (FDA) after researchers reported that it can slow down the progression of the disease by several months in some patients.

The drug, developed by Eli Lilly and Co., is the second Alzheimer's treatment to be shown to delay the disease, following the recent approval of Lecanemab, also known as Leqembi, from Eisai.

While Donanemab has shown promising results, it also carries a serious side effect of brain swelling or bleeding, which was linked to three deaths in clinical trials.

Despite this, scientists are hopeful that this new class of drugs, known as antibodies that target amyloid build-up in the brain, could mark a new era in Alzheimer's therapy.

However, experts caution that there are still many questions to be answered about which patients should receive these treatments and how much benefit they can expect.

Alzheimer's disease is a degenerative condition that affects memory and cognitive ability, and there is currently no cure.